RNS Number : 4266H
Life Science REIT PLC
09 October 2024
 

9 October 2024

LEI: 213800RG7JNX7K8F7525

A green rectangle with white text Description automatically generated with medium confidence

Life Science REIT plc

("Life Science REIT" or the "Company")

Pro Cam re-commits to Cambourne Park

Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life sciences properties, announces that Pro Cam UK Limited ("Pro Cam"), an agri-tech business, has signed an Agreement for Lease over 4,300 sq ft of space at Building 2030, at Cambourne Park Science & Technology Campus ("Cambourne Park"). The lease becomes effective on completion of Pro Cam's fit out of its new space, which is expected to be in December. 

Pro Cam, which is relocating from Building 2020 where it currently occupies 7,400 sq ft, has agreed a new five year lease at an increased rent of £25.0 psf, up 8.2% compared to its current rent of £23.1 psf. The rent will increase to £30.0 psf in year four. 

This transaction also creates an opportunity for further fully fitted lab repurposing. The space Pro Cam is vacating is on the second floor at Building 2020, where Life Science REIT is currently delivering four fully fitted labs, due to complete in Q424. Interest in the space has been very encouraging, with all four suites currently the subject of lease negotiations. The project delivers a yield on cost of c. 7% and a profit on cost of c. 25%. 

With a strong uptick in occupier interest since the start of the second half, over 90% of the 44,500 sq ft of vacant space at Cambourne Park is now under offer or in advanced negotiations. 

Ian Harris, Director of Asset Management at Ironstone Asset Management, the Company's Investment Adviser, said: "Pro Cam is a great example of the diversity of life science occupier we are attracting to the park, and supporting existing occupiers with their space requirements as they evolve, is a key element of our strategy. Pro Cam's move also creates a future opportunity to do more fully fitted lab space, which delivers attractive returns for the Company and further establishes Cambourne as a major life sciences destination."

Established in 1979, Pro Cam has built up a network of specialist regional businesses covering the whole of the UK who work with producers to increase the yield from their arable businesses. It has expanded in recent years to include crop nutrition, precision farming and biological products. 

Cambourne Park was acquired in 2021 with the intention of repositioning it as a dedicated science and technology hub.  It comprises six buildings over 230,000 sq ft. 

END

Enquiries:

Ironstone Asset Management - Investment Adviser

 +44 20 3011 2160

Simon Farnsworth, Managing Director

Simon.farnsworth@ironstoneam.com


Joanna Waddingham, Head of Investor Relations and Corporate Affairs


Joanna.Waddingham@ironstoneam.com


 

 

Link Company Matters Limited - Company Secretary

 

labs_cosec@linkgroup.co.uk

 

 

 

Panmure Gordon (UK) Limited - Joint Corporate Broker

+44 20 7886 2500

Alex Collins / Tom Scrivens


 

 

Jefferies International Limited - Joint Corporate Broker

+44 20 7029 8000

Tom Yeadon / Oliver Nott 

 

 

 

G10 Capital Limited - AIFM

+44 20 7397 5450

Maria Baldwin


 

FTI - Financial PR

 

+44 20 3727 1000

Dido Laurimore/ Richard Gotla / Oliver Parsons


LifeScienceReit@fticonsulting.com


 

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is underpinned by strong structural drivers, including an ageing population and a supportive regulatory environment as well as the growing interdependence with technology, which is expanding the life science spectrum, driving strong demand for laboratory space.

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk. To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFSIFMAELSEFS
Life Science Reit (LSE:LABS)
過去 株価チャート
から 10 2024 まで 11 2024 Life Science Reitのチャートをもっと見るにはこちらをクリック
Life Science Reit (LSE:LABS)
過去 株価チャート
から 11 2023 まで 11 2024 Life Science Reitのチャートをもっと見るにはこちらをクリック